已公布的药物有效性比较研究的特点
Michael Hochman1, Danny McCormick
1Department of Medicine, Cambridge Health Alliance, Cambridge and Harvard Medical School, Boston, Massachusetts, USA. mhochman@usc.edu
JAMA
|March 11, 2010
概括
在顶级期刊上大约三分之一的药物研究是比较有效性 (CE) 研究. 大多数CE研究都是非商业性资助的,很少关注安全性或成本效益.
科学领域:
- 药理学 药理学是指药理学的学科.
- 医疗保健服务研究 医疗服务研究
- 临床试验 临床试验
背景情况:
- 越来越多的人对医学中比较有效性 (CE) 研究的需求.
- 对现有CE研究的特征的理解有限.
研究的目的:
- 描述最近发表的评价药物的CE研究.
- 分析CE研究中的比较类型,结果,资金和研究设计.
主要方法:
- 随机试验,观察性研究和药物的元分析的分析.
- 从2008年6月到2009年9月,在6个具有影响力的通用和内科医学期刊上发表.
- 在CE研究 (比较活性治疗) 和非CE研究 (新疗法或非活性对照) 之间进行区分.
主要成果:
- 在328项药物研究中,有104项被确定为CE研究.
- CE研究主要比较不同的药物 (43%) 或药理学策略 (31%).
- 很少有CE研究关注安全性 (19%) 或成本效益 (2%).
- 欧洲经济学研究更有可能获得非商业资金 (87%),而不是商业资金 (13%).
- 活动对照器随机试验比非活动对照试验报告积极结果的可能性较小.
结论:
- 大约三分之一的大型期刊上的药物研究是CE研究.
- 少数CE研究研究药理与非药理疗法,安全性或成本.
- 非商业性资金,特别是政府赠款,主要支持CE研究.
更多相关视频
相关概念视频
Bioequivalence: Overview
2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
407
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
407
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
419
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
419
Bioequivalence Data: Statistical Interpretation
357
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
357
Bioequivalence of Drugs: Drugs with Multiple Indications
230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230


